Stephen J. Aldington

Stephen J. Aldington

Auto-generated profile, based on publicly available information

Stephen J. Aldington

Gloucestershire Hospitals National Health Service Foundation Trust, Cheltenham, U.K.

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 1998 in The Lancet
Verified
Journal Article
Closed access
RTRc Turner
Rc Turner
RHRr Holman
Rr Holman
CCCa Cull
Ca Cull
ISIm Stratton
Im Stratton
MAMatthews
Matthews
UGUkpds Grp
Ukpds Grp

5 February 2001 in Diabetologia
Verified
Journal Article
Open access
PDF file
ISI M Stratton
I M Stratton
EKE M Kohner
E M Kohner
SAS J Aldington
S J Aldington
RTR C Turner
R C Turner
RHR R Holman
R R Holman
DMD R Matthews
D R Matthews
Aims/hypothesis. To determine risk factors related to the incidence and progression of diabetic retinopathy over 6 years from diagnosis of Type II (non-insulin-dependent) diabetes mellitus. Methods. This report describes 1919 patients from within the United Kingdom Prospective Diabetes Study (UKPDS), with retinal photographs taken at diagnosis and 6 years later and with complete data available. Photographs were centrally graded for lesions of diabetic retinopathy using the modified Early Treatment of Diabetic Retinopathy Study Final scale. Risk factors were assessed after 3 months diet from the time of diagnosis of diabetes. Patients were seen every 3 months in a hospital setting. Biochemical measurements were done by a central laboratory. End points of vitreous haemorrhage and photocagulation were confirmed by independent adjudication of systematically collected clinical data. The main outcome measures were incidence and progression of retinopathy defined as a two-step Early Treatment of Diabetic Retinopathy Study (ETDRS) final scale change. Results. Of the 1919 patients, 1216 (63 %) had no retinopathy at diagnosis. By 6 years, 22 % of these had developed retinopathy, that is microaneurysms in both eyes or worse. In the 703 (37 %) patients with retinopathy at diagnosis, 29 % progressed by two scale steps or more. Development of retinopathy (incidence) was strongly associated with baseline glycaemia, glycaemic exposure over 6 years, higher blood pressure and with not smoking. In those who already had retinopathy, progression was associated with older age, male sex, hyperglycaemia (as evidenced by a higher HbA1 c) and with not smoking. Conclusion/interpretation. The findings re-emphasise the need for good glycaemic control and assiduous treatment of hypertension if diabetic retinopathy is to be minimised. [Diabetologia (2001) 44: 156–163]

1 April 2020 in The Lancet Diabetes & Endocrinology
Verified
Journal Article
Closed access
SVStela Vujosevic
Stela Vujosevic
SAStephen J Aldington
Stephen J Aldington
PSPaolo Silva
Paolo Silva
CHCristina Hernández
Cristina Hernández
PSPeter Scanlon
Peter Scanlon
Rafael SimóRafael Simó
Rafael Simó

1 March 1998 in Archives of Ophthalmology (1950)
Verified
Journal Article
Open access
PDF file
EKEva M. Kohner
Eva M. Kohner
SAStephen J. Aldington
Stephen J. Aldington
ISIrene M. Stratton
Irene M. Stratton
SMSusan E. Manley
Susan E. Manley
RHRury R. Holman
Rury R. Holman
RTRobert C. Turner
Robert C. Turner
THE UNITED Kingdom Prospective Diabetes Study (UKPDS) is a multicenter, randomized, controlled clinical trial of therapy in patients with newly diagnosed non–insulin-dependent diabetes mellitus (NIDDM) that aims to determine whether improved blood glucose control will prevent microvascular and macrovascular morbidity and mortality and whether any specific therapy is advantageous or disadvantageous. Details of the study design and randomization have been described previously.1,2 In brief, patients with newly diagnosed NIDDM were treated for 3 months with diet only, and if the fasting plasma glucose level was not adequately controlled at the end of this time, were randomized into treatment by diet only, oral agents, sulfonylureas (chlorpropamide, glyburide, or glipizide), or insulin. In addition, obese patients (≥120% of ideal body weight) were also randomized to be treated with the biguanide agent metformin. The study started in 1977, and retinal photography was included during 1983.

1 November 2004 in Archives of Ophthalmology (1950)
Verified
Journal Article
Closed access
PDF file
DMDavid R Matthews
David R Matthews
ISIrene M Stratton
Irene M Stratton
SAStephen J Aldington
Stephen J Aldington
RHRury R Holman
Rury R Holman
EKEva M Kohner
Eva M Kohner
UGUK Prospective Diabetes Study Group
UK Prospective Diabetes Study Group
Research from JAMA Ophthalmology — Risks of Progression of Retinopathy and Vision Loss Related to TightBlood Pressure Control in Type 2 Diabetes Mellitus — UKPDS 69

24 November 2003 in Diabetic Medicine
Verified
Journal Article
Closed access
PDF file
SHS. Harding
S. Harding
RGR. Greenwood
R. Greenwood
SAS. Aldington
S. Aldington
JGJ. Gibson
J. Gibson
DOD. Owens
D. Owens
TPThe Diabetic Retinopathy Grading and Disease Management Working Party
The Diabetic Retinopathy Grading and Disease Management Working Party